Donor-Lung Preservation Device Approved
TUESDAY, Aug. 12, 2014 (HealthDay News) -- The XVIVO Perfusion System has been approved by the U.S. Food and Drug Administration to help preserve donor lungs that ultimately may be used for transplant, the agency said Tuesday in a news release.
The device is expected to be used to preserve lungs that initially may not meet transplant criteria but could be used after doctors have been given more time to evaluate the organ, the agency said.
Transplant is an option for people with severe lung problems, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or idiopathic pulmonary fibrosis, the FDA said.
The just-approved device can be used to warm donor lungs to the appropriate temperature and flush lung tissue with a sterile solution called STEEN, the agency explained. The device also provides oxygen to the donor organ's cells for up to four hours.
Device manufacturer XVIVO Perfusion, based in Englewood, Colo., will be required to conduct a post-approval study of the device's long-term effects and any adverse reactions, the FDA said.
More information
Visit the FDA for more about this approval.
Related Articles
Search Allergy Articles
FDA Wants More Data on First Needle-Free Antidote for Severe Allergic Reactions
FDA Approves Drug for Cats With Allergic Skin Disease
What Is Chronic Sinusitis, and How Is it Treated?
FDA Panel Recommends Approval of First Nasal Spray to Combat Severe Allergy Attacks
FDA Expands Use of Asthma Med Xolair to Treat Food Allergies
Parents Scrambling After Asthma Inhaler Flovent Removed From Market
Move to Electric Vehicles Could Prevent Millions of Child Asthma Attacks Each Year
RSV in Infancy Could Raise a Child's Risk for Asthma
Canadian Wildfire Smoke Caused Spikes in Asthma-Related ER Visits Across the U.S.